TAG and COVID-19 Prevention Network Fall 2020 Webinars
TAG is hosting a series of webinars on COVID-19 biomedical prevention research in collaboration with the CoVPN. Information and videos from the first two events may be found on this page.
US FDA COVID Vaccine Authorization Important Step Toward Ending the COVID-19 Pandemic
Today’s decision by the US Food and Drug Administration (FDA) to grant an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA vaccine is an important step toward bringing the COVID-19 pandemic under control in the United States.
2020 Report on TB Research Funding Trends
TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2019 and analyzes trends in funding since 2005.
Investment in HIV Research Profoundly Benefits the COVID-19 Response
This policy brief discusses how investment in HIV research has profoundly benefitted the COVID-19 response, and advocates that continued financial support for HIV science can both ensure progress on COVID-19 and avoid losing ground—and lives—in the fight to end the HIV epidemic.
COVID-19 and Impacted Communities: A Media Communications Guide
This easy-to-use guide is designed to provide journalists and communication professionals the tools needed to ensure accurate reporting and curb any related stigma associated with the novel coronavirus SARS-COV-2, also known and reported as COVID-19. We invite you to use this to inform your own writing and to share it with colleagues and cohorts that work in media and communications.
Treatment Action Group Statement on Early Findings from HPTN 084
Treatment Action Group welcomes the announcement that the phase 3 HPTN 084 trial proved that intramuscular injections of ViiV’s long acting cabotegravir (CAB-LA) every eight weeks were superior to daily oral TDF/FTC pre-exposure prophylaxis (PrEP) in preventing new HIV infections in cisgender women in sub-Saharan Africa.
Treatment Action Group and AVAC Statement on Pfizer/BioNTech COVID-19 Vaccine Efficacy Announcement
Treatment Action Group (TAG) and AVAC welcome today’s announcement that preliminary data from the efficacy trial of Pfizer/BioNTech’s mRNA COVID-19 vaccine indicates a high level of protection against COVID-19. Our organizations urge caution, however, given the very limited information that is available only through a company press release.
Letter to Special Rapporteur on Cultural Rights
Our current letter follows an earlier letter dated June 23, 2020 and calls on the Special Rapporteur for cultural rights to explicitly acknowledge the human rights dimensions of science and reaffirm the right of everyone to participate in and enjoy the benefits of scientific progress and its applications in her forthcoming communication with the United Nations General Assembly on COVID-19.
Finally—A New Four-Month Treatment for Drug-Susceptible TB!
Treatment Action Group (TAG) and the Community Research Advisors Group (CRAG) welcome the news of a safe and effective regimen for shortening tuberculosis (TB) treatment to just four months.
Por fin un nuevo tratamiento de cuatro meses para la tuberculosis sensible a fármacos
El Grupo de Acción para el Tratamiento (TAG, por sus siglas en inglés) y el Grupo de Asesores Comunitarios de Investigación (CRAG, por sus siglas en inglés) se congratulan ante la noticia de un régimen seguro y eficaz capaz de acortar el tratamiento de la tuberculosis (TB) a sólo cuatro meses.